Epilepsy Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biop

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Epilepsy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Epilepsy Pipeline Report: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years.
• Epilepsy companies working in the treatment market are Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., Engage Therapeutics, Takeda, GW Pharmaceuticals, Avicanna, and others, are developing therapies for the Epilepsy treatment
• Emerging Epilepsy therapies in the different phases of clinical trials are- Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, Alprazolam inhalation, XEN1101, TAK-935, Cannabidivarin, AVCN-319302, and others are expected to have a significant impact on the Epilepsy market in the coming years.
• In March 2023, Preclinical data supporting IAMA Therapeutics' IAMA-6 programme in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, which will be held from April 22-27 in Boston, Massachusetts. IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to improve the lives of people suffering from brain disorders.
• In February 2023, The Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy was completed, according to an announcement from Addex Therapeutics. Metabotropic glutamate type 2 (mGlu2) receptor-positive allosteric modulator (PAM) ADX71149 is selective. The experiment is being run by Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson's Janssen Pharmaceutical Companies.
• In January 2023, EQU-001, a novel anti-inflammatory anti-seizure drug, is administered as once-daily oral adjunctive therapy for focal seizures in adults with epilepsy. Equilibre Biopharmaceuticals Corp. reported positive topline results from the Phase 2 clinical trial evaluating the clinical safety, tolerability, and preliminary efficacy of EQU-001. The EQU-001 study's findings are positive since they show outstanding tolerability and encouraging efficacy for adult patients with focal epilepsy, particularly for those who have seizures that are challenging to manage.
• In January 2023, A cutting-edge electronic diary (eDiary) data capturing technology was launched by Signant Health with the aim of streamlining the epilepsy trial participation experience for patients and research sites while assuring reliable outcome assessment data to support trial endpoints. The novel patient-reported outcome measure, which was created in partnership with The Epilepsy Study Consortium (TESC), offers clinical research sponsors and organisations a standardised way to gather common seizure data items with high-quality data.
• In June 2022, Preclinical research from CODA Biotherapeutics, Inc.'s focal epilepsy programme showed that using the company's lead-engineered receptor and small molecule activator medication considerably decreased the frequency of focal seizures in vivo. The pharmacokinetics of the activator medication in mice models were shown to be consistent with the quick reduction in seizures, according to the results. Data also showed a strong correlation between a decrease in seizure frequency and the expression of CODA's lead receptor.

Epilepsy Overview
A chronic neurological condition called epilepsy is characterised by frequent, recurrent convulsions that cause strange behaviour. Due to the various seizure forms, underlying conditions, and varying degrees of severity, it may qualify as a spectrum disorder.

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:
• Kv7 Program: Elium Therapeutics
• CG 01: CombiGene
• OV329: Ovid Therapeutics
• OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
• SKL24741: SK Biopharmaceuticals
• RLS103: Receptor Life Sciences
• CT-010: Cerebral Therapeutics
• EQU 001: Equilibre Biopharmaceuticals
• Darigabat: Cerevel Therapeutics
• ENX-101: Engrail Therapeutics
• AMZ002: Amzell
• XEN496: Xenon Pharmaceuticals Inc.
• Alprazolam inhalation: Engage Therapeutics
• XEN1101: Xenon Pharmaceuticals
• TAK-935: Takeda Pharmaceuticals
• Cannabidivarin: GW Pharmaceuticals
• AVCN-319302: Avicanna

Epilepsy Route of Administration
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Epilepsy Molecule Type
Epilepsy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Epilepsy Pipeline Therapeutics Assessment
• Epilepsy Assessment by Product Type
• Epilepsy By Stage and Product Type
• Epilepsy Assessment by Route of Administration
• Epilepsy By Stage and Route of Administration
• Epilepsy Assessment by Molecule Type
• Epilepsy by Stage and Molecule Type

DelveInsight's Epilepsy Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies at:
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Epilepsy Therapeutics Market include:
Key companies developing therapies for Epilepsy are - Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics, Equilibre Biopharmaceuticals, ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics, Cerebral Therapeutics, Engrail Therapeutics, and others.

Epilepsy Pipeline Analysis:
The Epilepsy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
• Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Epilepsy drugs and therapies-
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Epilepsy Pipeline Market Drivers
• Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

Epilepsy Pipeline Market Barriers
• However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

Scope of Epilepsy Pipeline Drug Insight
• Coverage: Global
• Key Epilepsy Companies: Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., Engage Therapeutics, Takeda, GW Pharmaceuticals, Avicanna, and others
• Key Epilepsy Therapies: Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, Alprazolam inhalation, XEN1101, TAK-935, Cannabidivarin, AVCN-319302, and others
• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
• Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Epilepsy Report Introduction
2. Epilepsy Executive Summary
3. Epilepsy Overview
4. Epilepsy- Analytical Perspective In-depth Commercial Assessment
5. Epilepsy Pipeline Therapeutics
6. Epilepsy Late Stage Products (Phase II/III)
7. Epilepsy Mid Stage Products (Phase II)
8. Epilepsy Early Stage Products (Phase I)
9. Epilepsy Preclinical Stage Products
10. Epilepsy Therapeutics Assessment
11. Epilepsy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Epilepsy Key Companies
14. Epilepsy Key Products
15. Epilepsy Unmet Needs
16 . Epilepsy Market Drivers and Barriers
17. Epilepsy Future Perspectives and Conclusion
18. Epilepsy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Epilepsy Market https://www.delveinsight.com/report-store/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Epilepsy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Epilepsy Epidemiology https://www.delveinsight.com/report-store/epilepsy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Epilepsy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.